Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
32.71 USD | +9.07% | +9.11% | 0.00% |
24/05 | Sector Update: Health Care Stocks Softer in Friday Afternoon Trading | MT |
24/05 | CG Oncology Shares Jump After Potential Combination Therapy for Bladder Cancer Meets Phase 2 Primary Endpoint | MT |
Business Summary
Number of employees: 61
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Bladder-sparing Therapeutic
100.0
%
| 0 | 100.0 % | 0 | 100.0 % | +6.81% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 0 | 100.0 % | 0 | 100.0 % | +6.81% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Arthur Kuan
CEO | Chief Executive Officer | 34 | 30/17/30 |
Ambaw Bellete
PSD | President | 54 | 01/23/01 |
Vijay Kasturi
CTO | Chief Tech/Sci/R&D Officer | 57 | 01/23/01 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Susan Graf
BRD | Director/Board Member | 52 | 20/11 |
Leonard Post
BRD | Director/Board Member | 72 | 22/18/22 |
Victor Tong
BRD | Director/Board Member | 41 | 01/23/01 |
James Mulé
BRD | Director/Board Member | 72 | 22/18/22 |
Arthur Kuan
CEO | Chief Executive Officer | 34 | 30/17/30 |
Hong Fang Song
BRD | Director/Board Member | 59 | 01/15/01 |
Brian Liu
BRD | Director/Board Member | 36 | 01/22/01 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 66,640,150 | 61,943,223 ( 92.95 %) | 0 | 92.95 % |
Company contact information
Sector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
0.00% | 217.98Cr | |
+67.53% | 6.39TCr | |
-0.77% | 4.18TCr | |
+44.98% | 4.07TCr | |
-10.87% | 2.71TCr | |
+13.30% | 2.65TCr | |
-22.79% | 1.87TCr | |
+4.70% | 1.27TCr | |
+24.10% | 1.21TCr | |
+27.41% | 1.21TCr |
- Stock Market
- Equities
- CGON Stock
- Company CG Oncology, Inc.